Sign in

Private company

Cardiovascular Systems Inc

American surgical and medical instruments and apparatus company2

In its 2022 annual report the company says: “We are a medical technology company leading the way in the effort to successfully treat patients suffering from peripheral and coronary artery diseases, including those with arterial calcium, the most difficult form of arterial disease to treat. We are committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve the lives of patients facing this difficult disease state.”80 It is headquartered in Wilmington, United States.2

Last updated Oct 21, 2026.

Overview

$236.2MRevenue, fiscal 20223
-$36.9MNet income, fiscal 20223
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersWilmington, United States2
  • Incorporated inDE4
  • Business address1225 Old Hwy 8 Nw, St. Paul, Mn 551124
  • Filer categoryLarge accelerated filer4
  • Legal formCorporation2
  • LEI549300NUBWKJMNMQ32872
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 33254952

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

73.1%Gross margin3
-15.2%Operating margin3
-15.6%Net margin3
-8.8%Revenue growth, 20223
-14.8%Return on equity3
-$28.5MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue23¢$63.4M
  • Research and development13¢$36.7M
  • Selling, general and admin63¢$170.5M
  • Interest1¢$1.6M
  • Income tax0¢$310.0K

Out of $236.2M in revenue.3 The company lost money this year.

Financial statements

Revenue567893$236.2M in 2022+30% since 2015
0$100.0M$200.0M$300.0M2015: $181.5M$181.5M20152016: $178.2M$178.2M2016−2%2017: $204.9M$204.9M2017+15%2018: $217.0M$217.0M2018+6%2019: $248.0M$248.0M2019+14%2020: $236.5M$236.5M2020−5%2021: $259.0M$259.0M2021+9%2022: $236.2M$236.2M2022−9%
Gross profit567893$172.8M in 2022+22% since 2015
0$100.0M$200.0M$300.0M2015: $142.0M$142.0M20152016: $142.8M$142.8M2016+1%2017: $165.5M$165.5M2017+16%2018: $177.6M$177.6M2018+7%2019: $200.3M$200.3M2019+13%2020: $187.8M$187.8M2020−6%2021: $197.8M$197.8M2021+5%2022: $172.8M$172.8M2022−13%
Operating income567893-$35.8M in 2022+10% since 2015
-$60.0M-$40.0M-$20.0M0$20.0M2015: -$32.6M-$32.6M20152016: -$56.1M-$56.1M2016+72%2017: -$1.5M-$1.5M2017−97%2018: $2.2M$2.2M20182019: -$825.0K-$825.0K20192020: -$26.8M-$26.8M2020+3145%2021: -$11.9M-$11.9M2021−55%2022: -$35.8M-$35.8M2022+200%
Net income567893-$36.9M in 2022+13% since 2015
-$60.0M-$40.0M-$20.0M0$20.0M2015: -$32.8M-$32.8M20152016: -$56.0M-$56.0M2016+71%2017: -$1.8M-$1.8M2017−97%2018: $1.7M$1.7M20182019: -$255.0K-$255.0K20192020: -$27.2M-$27.2M2020+10581%2021: -$13.4M-$13.4M2021−51%2022: -$36.9M-$36.9M2022+175%
Fiscal year20152016201720182019202020212022
Revenue$181.5M5$178.2M6$204.9M7$217.0M8$248.0M9$236.5M3$259.0M3$236.2M3
Cost of revenue$39.5M5$35.4M6$39.4M7$39.5M8$47.7M9$48.8M3$61.1M3$63.4M3
Gross profit$142.0M5$142.8M6$165.5M7$177.6M8$200.3M9$187.8M3$197.8M3$172.8M3
Research and development$31.0M5$25.9M6$22.9M7$26.6M8$33.2M9$43.4M3$41.1M3$36.7M3
Selling, general and admin$143.7M5$162.5M6$144.1M7$148.6M8$167.7M9$170.0M3$167.5M3$170.5M3
Operating expenses$208.6M3
Operating income-$32.6M5-$56.1M6-$1.5M7$2.2M8-$825.0K9-$26.8M3-$11.9M3-$35.8M3
Interest$23.0K5$06$500.0K7$1.7M8$1.7M9$2.0M3$1.7M3$1.6M3
Income before tax-$36.6M3
Income tax$114.0K5$92.0K6$86.0K7$132.0K8$190.0K9$231.0K3$252.0K3$310.0K3
Net income-$32.8M5-$56.0M6-$1.8M7$1.7M8-$255.0K9-$27.2M3-$13.4M3-$36.9M3
Earnings per share-$1.726-$0.067$0.058-$0.018-$0.793-$0.353-$0.943
Earnings per share (diluted)-$1.726-$0.067$0.058-$0.018-$0.793-$0.353-$0.943
Shares (weighted, basic)39.2M shares3
Shares (weighted, diluted)39.2M shares3

Compare Cardiovascular Systems Inc with another company

Corporate structure

Cardiovascular Systems Inc is part of a group headed by Abbott Laboratories. 542 entities, 71 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cardiovascular Systems Inc

  • Champlain Investment Partners, LLC Filed SC 13G/A on Cardiovascular Systems Inc, latest Feb 13, 2024 (3 filings since Feb 11, 2022)
  • BROWN CAPITAL MANAGEMENT LLC Filed SC 13G/A on Cardiovascular Systems Inc, latest Feb 14, 2023 (3 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on Cardiovascular Systems Inc, latest Feb 9, 2023 (2 filings since Feb 9, 2022)
  • BlackRock Filed SC 13G/A on Cardiovascular Systems Inc, latest Jan 26, 2023 (3 filings since Jan 28, 2022)
  • Abbott Laboratories Green Oaks, Illinois, United States
    • Abbott (France) Paris, France
    • Abbott (India) Mumbai, India
    • Abbott Japan 东京, Japan
    • Alere Chicago, Illinois, United States
      • Alere (Germany) Subsidiary · Jena, Germany
      • Alere (Norway) Subsidiary · Oslo, Norway
      • Alere Wellbeing Subsidiary · Seattle, United States
      • ABBOTT DIAGNOSTICOS RAPIDOS S.A. Subsidiary · North Chicago, Illinois, United States
      • ABBOTT DIAGNOSTICS MEDICAL PRIVATE LIMITED Subsidiary · Abbott Park, Illinois, United States
      • Abbott Rapid Diagnostics AB Subsidiary · North Chicago, Illinois, United States
      • ABBOTT RAPID DIAGNOSTICS LIMITED Subsidiary · Abbott Park, Illinois, United States
      • ABBOTT RAPID DX INTERNATIONAL LIMITED Subsidiary · Galway, Ireland
      • ABBOTT TOXICOLOGY LIMITED Subsidiary · Abbott Park, Illinois, United States
        • COZART LIMITED Subsidiary · North Chicago, Illinois, United States
      • Alere (Australia) Subsidiary · Australia
      • Alere (Switzerland) Subsidiary · Switzerland
      • Alere (United Kingdom) Subsidiary · United Kingdom
      • AXIS-SHIELD DIAGNOSTICS LIMITED Subsidiary · Abbott Park, Illinois, United States
      • TWISTDX LIMITED Subsidiary · Lake Bluff, Illinois, United States
      • UNIPATH LIMITED Subsidiary · North Chicago, Illinois, United States
    • Cardiovascular Systems Inc Wilmington, Delaware, United States
    • Abbott (Canada) Subsidiary · Montreal, Canada
    • Abbott (Chile) Subsidiary
    • Abbott (Germany) Subsidiary · Wiesbaden, Germany
    • Abbott (South Korea) Subsidiary · Seoul, South Korea
    • Abbott (United Kingdom) Subsidiary · Maidenhead, United Kingdom
    • Abbott Spain Subsidiary · Madrid, Spain
    • Veropharm Subsidiary · Moscow, Russia
    • 주식회사 한국애보트진단 Subsidiary · 100% · 용인시, South Korea
    • "Abbott Laboratories Baltics" Subsidiary · Latvia
    • "Veropharm" Limited Liability Company Subsidiary · Ukraine
    • 3-102-920937, Sociedad de Responsabilidad Limitada Subsidiary · Costa Rica
    • 3A Nutrition (Vietnam) Company Limited Subsidiary · Vietnam
    • ABBOTT Subsidiary · Wavre, Belgium
    • ABBOTT (JIAXING) NUTRITION CO. LTD. Subsidiary · 嘉兴, China
    • Abbott (Shanghai) Diagnostics Sales Co., Ltd. Subsidiary · China
    • Abbott (UK) Finance Limited Subsidiary · United Kingdom
    • Abbott (UK) Holdings Limited Subsidiary · United Kingdom
    • Abbott Affiliate Holdings B.V. Subsidiary · Netherlands
    • ABBOTT AG Subsidiary · Baar, Switzerland
    • Abbott Asia Holdings Limited Subsidiary · Maidenhead, United Kingdom
    • and 503 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cardiovascular Systems Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$54.2M3 Jun 30, 2022$51.2M3 Jun 30, 2021+5.8%
Accumulated depreciation$25.2M3 Jun 30, 2022$22.3M3 Jun 30, 2021+12.7%
Property and equipment, net$29.0M3 Jun 30, 2022$28.9M3 Jun 30, 2021+0.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$66.4M3 Jun 30, 2022$71.1M3 Jun 30, 2021−6.5%
Marketable securities, current$93.4M3 Jun 30, 2022$136.0M3 Jun 30, 2021−31.3%
Marketable securities, non-current$4.8M3 Jun 30, 2022$5.7M3 Jun 30, 2021−16.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$19.9M3 Jun 30, 2022$18.2M3 Jun 30, 2021+9.3%
Accumulated amortization$4.2M3 Jun 30, 2022$2.9M3 Jun 30, 2021+46.7%
Finite-lived intangibles, net$15.7M3 Jun 30, 2022$15.4M3 Jun 30, 2021+2.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$34.6M3 Jun 30, 2022$32.3M3 Jun 30, 2021+7.0%
Raw materials$13.8M3 Jun 30, 2022$11.6M3 Jun 30, 2021+18.6%
Work in process$2.8M3 Jun 30, 2022$3.5M3 Jun 30, 2021−19.7%
Finished goods$18.0M3 Jun 30, 2022$17.2M3 Jun 30, 2021+4.5%

Leadership

Who has led Cardiovascular Systems Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kenneth J. Collins2006–2008
  2. Scott R. Ward2015–2023

Chair

  1. Scott R. Ward2019–2023

President

  1. Kenneth J. Collins2006–2008
  2. Scott R. Ward2015–2018

Chief financial officer

  1. Mark L. Smith2006–2008
  2. Laurence L. Betterley2009–2017
  3. Jeffrey S. Points2018–2023

Chief operating officer

  1. Kevin J. Kenny2015–2017
  2. Rhonda J. Robb2018–2022
2010201520202025
Board members and other officers (41)

Former names

  • REPLIDYNE INCAug 12, 2002 to Mar 3, 20094

Timeline

  1. Apr 27, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights62
  2. Apr 13, 20238-K Other events63
  3. Feb 9, 20238-K Results of operations64
  4. Feb 9, 20238-K Entered a material agreement; Executive or director change; Regulation FD disclosure65
  5. Jan 3, 20238-K Entered a material agreement66
  6. Nov 10, 20228-K Shareholder vote67
  7. Nov 3, 20228-K Results of operations68
  8. Aug 3, 20228-K Results of operations69
  9. Aug 3, 20228-K Regulation FD disclosure70
  10. Jul 22, 20228-K Executive or director change71
  11. Jun 7, 20228-K Executive or director change72
  12. May 4, 20228-K Results of operations73
  13. Dec 3, 2015New chief executive Scott R. Ward becomes CEO14
  14. Jun 27, 2006New chief executive Kenneth J. Collins becomes CEO15
  15. Dec 5, 2000Founded Cardiovascular Systems Inc is founded2

Calendar

When it reported results

  1. Feb 9, 2023Reported quarterly or annual results64
  2. Nov 3, 2022Reported quarterly or annual results68
  3. Aug 3, 2022Reported quarterly or annual results69
  4. May 4, 2022Reported quarterly or annual results73
  5. Feb 3, 2022Reported quarterly or annual results74
  6. Nov 9, 2021Reported quarterly or annual results75

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

131 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 18 major events, 58 insider forms, 11 large holders, 38 other. The latest 20:

  1. Feb 13, 2024SC 13G/A CHAMPLAIN 13G TICKER CSII EDGAR
  2. May 8, 202315-12G EDGAR
  3. May 1, 2023S-8 POS EDGAR
  4. May 1, 2023S-8 POS EDGAR
  5. May 1, 2023S-8 POS EDGAR
  6. May 1, 2023S-8 POS EDGAR
  7. May 1, 2023S-8 POS EDGAR
  8. May 1, 2023S-8 POS EDGAR
  9. May 1, 2023S-8 POS EDGAR
  10. May 1, 2023S-8 POS EDGAR
  11. May 1, 2023S-8 POS EDGAR
  12. May 1, 2023S-8 POS EDGAR
  13. May 1, 2023S-8 POS EDGAR
  14. May 1, 2023S-8 POS EDGAR
  15. May 1, 2023S-8 POS EDGAR
  16. May 1, 2023S-8 POS EDGAR
  17. May 1, 2023S-8 POS EDGAR
  18. May 1, 2023S-8 POS EDGAR
  19. May 1, 2023S-8 POS EDGAR
  20. May 1, 2023S-8 POS EDGAR

The 131 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 20, 2022Points Jeffrey S.Chief Financial OfficerBuy3,000$14.50$43.5KForm 4
May 20, 2022Ward Scott R.Chairman and CEOBuy3,000$14.49$43.5KForm 4
Feb 23, 2022Paulsen ErikDirectorBuy500$19.05$9.5KForm 4
Feb 8, 2022Points Jeffrey S.Chief Financial OfficerBuy2,000$18.20$36.4KForm 4
Feb 7, 2022Aronson Martha GoldbergDirectorBuy2,500$18.43$46.1KForm 4
Feb 7, 2022Robb Rhonda J.Chief Operating OfficerBuy1,567$18.72$29.3KForm 4
Feb 7, 2022Ward Scott R.Chairman and CEOBuy2,500$18.52$46.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Cardiovascular Systems Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCardiovascular Systems Inc1
  • CIK0001180145
  • Employer ID (EIN)41-16980561
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsJune 301
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1225 Old Hwy 8 Nw, St. Paul, MN 551121
  • Phone651-259-16001
  • Shares outstanding41,958,938 as of Feb 7, 202311
  • Public float$736.5M as of Dec 31, 20213
  • On EDGAR sinceAug 12, 20021
  • Filings1,453 in all: 4 (757), 8-K (238), SC 13G/A (70), 3 (53), 10-Q (50), SC 13G (30), 4/A (21), S-8 POS (21)1
    All 50 form types

    DEFA14A (20), S-8 (20), 10-K (17), DEF 14A (16), SC 13D/A (14), CT ORDER (12), SD (9), UPLOAD (9), 425 (8), ARS (8), 424B5 (7), EFFECT (7), CORRESP (6), D/A (6), 5 (5), REGDEX (4), S-1/A (4), SC 13D (4), D (3), DEFR14A (3), REGDEX/A (3), S-3 (3), S-4/A (3), 144 (2), 3/A (2), POS AM (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 5/A (1), 8-A12G (1), 8-K/A (1), DEFM14A (1), FWP (1), PREM14A (1), S-1 (1), S-3/A (1), S-3ASR (1), S-3MEF (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Aug 18, 2022
    Quarterly report (10-Q) Feb 9, 2023
    Proxy statement (DEF 14A) Sep 28, 2022
    Latest 8-K (8-K) Apr 27, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
    SEC EDGAROther events
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80